Back to results
US 2026/0276657 A1Published application
Targets and methods of diagnosing, monitoring and treating frontotemporal dementia
AssigneeArizona Board of Regents on behalf of Arizona State University
InventorsMichael Sierks, Stephanie Williams
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antibodies, antibody fragments, binding agents, and compositions that specifically recognize protein variant biomarkers associated with frontotemporal dementia, kits and methods of use, including diagnosing, monitoring and treating frontotemporal dementia.
Claims20
A method of diagnosing a subject with frontotemporal dementia (FTD), the method comprising:
- contacting a biological sample from a subject at risk or suspected of having FTD with a single-chain variable fragment (scFv) reactive with one or more oligomeric beta amyloid disease variants, wherein the scFv reactive with one or more oligomeric beta amyloid disease variants has a light chain complementary determining region (CDR) and heavy chain CDR combination selected from the group consisting of:
- SEQ ID NOS:
- 21 (CDR-L1), 26 (CDR-L2), 43 (CDR-L3), 62 (CDR-H1), 66 (CDR-H2), and 85 (CDR-H3);
- and
- SEQ ID NOS:
- 21 (CDR-L1), 27 (CDR-L2), 44 (CDR-L3), 61 (CDR-H1), 67 (CDR-H2), and 85 (CDR-H3);
- and
- detecting binding between the scFvs and the biological sample, wherein the detection of binding between the scFv to the biological sample is indicative that the subject has or is likely to develop FTD.
5 more elements
A method of monitoring a subject with frontotemporal dementia (FTD), the method comprising:
- contacting a first biological sample from a subject diagnosed with FTD with a single-chain variable fragment (scFv) reactive with one or more oligomeric beta amyloid disease variants, wherein the scFv reactive with one or more oligomeric beta amyloid disease variants has a light chain complementary determining region (CDR) and heavy chain CDR combination selected from the group consisting of:
- SEQ ID NOS:
- 21 (CDR-L1), 26 (CDR-L2), 43 (CDR-L3), 62 (CDR-H1), 66 (CDR-H2), and 85 (CDR-H3);
- and
- SEQ ID NOS:
- 21 (CDR-L1), 27 (CDR-L2), 44 (CDR-L3), 61 (CDR-H1), 67 (CDR-H2), and 85 (CDR-H3);
- detecting binding between the one or more scFvs and the first biological sample;
- administering a treatment to the subject diagnosed with FTD;
- at a desired time, contacting a second biological sample obtained from the subject with one or more scFvs reactive with one or more oligomeric beta amyloid disease variants;
- and
- detecting binding between the one or more scFvs and the second biological sample.
8 more elements
A kit for detecting frontotemporal dementia (FTD), the kit comprising:
- a single-chain variable fragment (scFv) reactive with one or more oligomeric beta amyloid disease variants, wherein the scFv reactive with one or more oligomeric beta amyloid disease variants has a light chain complementary determining region (CDR) and heavy chain CDR combination selected from the group consisting of:
- SEQ ID NOS:
- 21 (CDR-L1), 26 (CDR-L2), 43 (CDR-L3), 62 (CDR-H1), 66 (CDR-H2), and 85 (CDR-H3);
- and
- SEQ ID NOS:
- 21 (CDR-L1), 27 (CDR-L2), 44 (CDR-L3), 61 (CDR-H1), 67 (CDR-H2), and 85 (CDR-H3);
- one or more controls;
- and
- instructions for using the kit.
6 more elements
Dependencies are inferred from the claim text.